Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : The Rational Analyst -- Ignore unavailable to you. Want to Upgrade?

To: Scott H. Davis who wrote (1049)	6/2/1998 12:38:00 AM
From: Scott H. Davis	Read Replies (1) \| Respond to of 1720

[Clarification, VICL comments] I got too involved rewriting a sentence, and lost my thought train. VICL's technology approach to preventative vaccines is "Nakid DNA". That is express enough of a pure DNA antigen to trigger an immune response, rather than the approach most of us have received, which is most often "live" vaccines. More chancy, and more risky than the antigen. This hits closer to home than most of you could appreciate. My son had a serious response to an MMR (live vaccine) shot at age 1. This triggered a GI tract sub-accute infection, leading to intestional permiability (leaky gut), to gluten peptides escaping the GI tract, forming pseudo-opiates, crossing the blood-brain barrier, effecting brain development and screwing up brain development, while the intestional permiability resulted in changes that resulted in serious nutritional malabsorbtion. The result was autism, ADHD and a load of related neuro/developmental issues. The VICL technology has a lot of promise in yielding safer and more effective vaccines. And vaccines for previously untreated indications. Such as Malaria. Think of the # of cases worldwide. Great social benefit, great revenue stream. Classic win/win. Scott